TTM
$2.06B
YoY change
+34.2%
5Y CAGR
+27.2%
Peak year (2025)
$1.94B
Cumulative gross profit
$9.13B
Gross Profit history chart for Insulet (PODD) from 2002 to 2025
Latest: $1.94B
Gross Profit growth chart for Insulet (PODD) from 2002 to 2025
Latest: +34.2%
Gross Profit history table for Insulet (PODD) from 2002 to 2025
| 2025 | $1.94B | +34.2% | +$494.20M | ||
| 2024 | $1.45B | +24.6% | +$285.80M | ||
| 2023 | $1.16B | +44.0% | +$354.30M | ||
| 2022 | $805.60M | +7.1% | +$53.50M | ||
| 2021 | $752.10M | +29.2% | +$169.80M | ||
| 2020 | $582.30M | +21.2% | +$102.00M | ||
| 2019 | $480.30M | +29.8% | +$110.13M | ||
| 2018 | $370.17M | +33.6% | +$93.00M | ||
| 2017 | $277.17M | +31.3% | +$66.08M | ||
| 2016 | $211.09M | +58.4% | +$77.81M | ||
| 2015 | $133.27M | -7.0% | −$10.02M | ||
| 2014 | $143.29M | +27.5% | +$30.89M | ||
| 2013 | $112.40M | +21.7% | +$20.07M | ||
| 2012 | $92.34M | +38.4% | +$25.62M | ||
| 2011 | $66.71M | +52.6% | +$22.99M | ||
| 2010 | $43.73M | +139.0% | +$25.43M | ||
| 2009 | $18.30M | -499.1% | +$22.88M | ||
| 2008 | −$4.58M | -62.9% | +$7.78M | ||
| 2007 | −$12.36M | +3.0% | −$364.00K | ||
| 2006 | −$12.00M | +710.6% | −$10.52M | ||
| 2005 | −$1.48M | — | −$1.48M | ||
| 2004 | $0.00 | — | $0.00 | ||
| 2003 | $0.00 | — | $0.00 | ||
| 2002 | $0.00 | — | — |
- 2025$1.94B+34.2%
- 2024$1.45B+24.6%
- 2023$1.16B+44.0%
- 2022$805.60M+7.1%
- 2021$752.10M+29.2%
- 2020$582.30M+21.2%
- 2019$480.30M+29.8%
- 2018$370.17M+33.6%
- 2017$277.17M+31.3%
- 2016$211.09M+58.4%
- 2015$133.27M-7.0%
- 2014$143.29M+27.5%
- 2013$112.40M+21.7%
- 2012$92.34M+38.4%
- 2011$66.71M+52.6%
- 2010$43.73M+139.0%
- 2009$18.30M-499.1%
- 2008−$4.58M-62.9%
- 2007−$12.36M+3.0%
- 2006−$12.00M+710.6%
- 2005−$1.48M—
- 2004$0.00—
- 2003$0.00—
- 2002$0.00—
Gross Profit values are taken from Insulet's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Gross Profit at Insulet (PODD)
According to Insulet's latest reported financial statements, the company's current gross profit (TTM) is $2.06B. Gross profit equals revenue minus the cost of goods sold (COGS) — what remains from sales after the direct cost of producing the product or service. It does not yet subtract operating expenses, interest, or taxes (see operating income and net income for those steps). Higher gross profit (and gross margin) generally signals pricing power and production efficiency.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Insulet (PODD) most recent annual gross profit stands at $1.94B (2025) – surged 34.2% year-over-year.
Through 2020–2025 (5 years), Insulet gross profit delivered a +27.2% annualised rate; sustaining 10 straight years of year-over-year growth.
$1.94B stands as the all-time-high annual gross profit, posted in 2025, against a low of −$12.36M during 2007.
Insulet Gross Profit by Year
Insulet Gross Profit 2025: $1.94B
Insulet posted gross profit of $1.94B in 2025, surged 34.2% from 2024. This figure represents the highest annual value in the available history.
Insulet Gross Profit 2024: $1.45B
In 2024, Insulet reported gross profit of $1.45B, grew 24.6% from 2023.
Insulet Gross Profit 2023: $1.16B
Insulet gross profit in 2023 was $1.16B, surged 44.0% from 2022.
Insulet Gross Profit 2022: $805.60M
2022's gross profit for Insulet came in at $805.60M, grew 7.1% from 2021.
Insulet Gross Profit 2021: $752.10M
Insulet gross profit in 2021 was $752.10M.
See more financial history for Insulet (PODD).
Sector peers by Gross Profit
Healthcare peers of Insulet (PODD), ranked by their latest gross profit
| $82.92B | |
| $68.56B | |
| $54.62B | |
| $48.11B | |
| $46.73B | |
| $42.96B | |
| $39.01B | |
| $26.01B |
- $82.92B
- $68.56B
- $54.62B
- $48.11B
- $46.73B
- $42.96B
- $39.01B
- $26.01B
Frequently asked questions
Insulet (PODD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation